BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.92 +2.27%
EPS Growth %: -43.8%
Financial Fact:
Product sales: 0
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -43.8%
Financial Fact:
Product sales: 0
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance
- GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
